Literature DB >> 14605283

Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients.

An S De Vriese1, Michel Langlois, Dirk Bernard, Inge Geerolf, Lut Stevens, Johan R Boelaert, Mario Schurgers, Ervé Matthys.   

Abstract

BACKGROUND: Hyperhomocysteinaemia is a putative risk factor for atherothrombotic cardiovascular disease in the haemodialysis population. High-dose vitamin B therapy does not entirely normalize elevated plasma total homocysteine (tHcy) levels in haemodialysis patients. Alternative therapies to reduce tHcy further are therefore required. Modifications of the dialysis regimen may result in a better removal of Hcy. We examined the effect of dialyser membrane pore size on tHcy levels in vitamin-replete chronic haemodialysis patients.
METHODS: Forty-five haemodialysis patients were dialysed during 4 weeks with a low-flux, a high-flux and a super-flux membrane, in random order. Pre-dialysis tHcy was determined at baseline and every 4 weeks. In 18 patients, plasma tHcy before and after dialysis and dialysate tHcy concentrations were measured.
RESULTS: Pre-dialysis tHcy decreased significantly during 4 weeks super-flux dialysis (-14.6 +/- 2.8%), whereas it remained stable during high-flux (+0.5 +/- 2.4%) and low-flux dialysis (+1.7 +/- 3.2%). The homocysteine reduction ratio was not different for the three membranes: 0.39 +/- 0.03 for the super-flux, 0.47 +/- 0.02 for the high-flux and 0.39 +/- 0.02 for the low-flux dialyser. The amount of Hcy recovered in the dialysate during a single dialysis session was also similar: 117.5 +/- 3.6 micro mol during super-flux, 95.3 +/- 11.5 micro mol during high-flux and 116.5 +/- 11.6 micro mol during low-flux dialysis.
CONCLUSION: Super-flux dialysis significantly lowers tHcy in chronic haemodialysis patients. Improved removal of middle-molecule uraemic toxins with inhibitory effects on Hcy-metabolizing enzymes, rather than better dialytic clearance of Hcy itself, may explain the beneficial effect of the super-flux membrane.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605283     DOI: 10.1093/ndt/gfg437

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 2.  Flummoxed by flux: the indeterminate principles of haemodialysis.

Authors:  Sudhir K Bowry; Fatih Kircelli; Madhukar Misra
Journal:  Clin Kidney J       Date:  2021-12-27

3.  Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

Authors:  Bradley L Urquhart; David J Freeman; Murray J Cutler; Rahul Mainra; J David Spence; Andrew A House
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 8.237

Review 4.  Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.

Authors:  A M Macleod; M Campbell; J D Cody; C Daly; C Donaldson; A Grant; I Khan; K S Rabindranath; L Vale; S Wallace
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 5.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

Review 6.  Liposomes to Augment Dialysis in Preclinical Models: A Structured Review.

Authors:  Kevin Hart; Martyn Harvey; Mingtan Tang; Zimei Wu; Grant Cave
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.